Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2146-2151

  Yang, Hannah P ^a   Anderson, William F ^a   Rosenberg, Philip S ^a   Trabert, Britton ^a   Gierach, Gretchen L ^a   Wentzensen, Nicolas ^a   Cronin, Kathleen A ^a   Sherman, Mark E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; DATA BASE; DETERIORATION; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL HORMONAL THERAPY; NORTH AMERICAN; OVARY CANCER; PRESCRIPTION; PRIORITY JOURNAL; RESIDENT; TREND STUDY; UNITED STATES; WOMEN'S HEALTH; DRUG EFFECTS; ESTROGEN THERAPY; HORMONE SUBSTITUTION; INCIDENCE; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; PROCEDURES; UTILIZATION;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; UNITED STATES;

EID: 84884490397     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.5758     Document Type: Article

References (36)

1. American Cancer Society: Cancer Facts & Figures. Atlanta, GA, American Cancer Society, 2012
2. Weiss NS, Szekely DR, Austin DF: Increasing incidence of endometrial cancer in the United States. N Engl J Med 294:1259-1262, 1976
3. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
4. Buist DS, Newton KM, Miglioretti DL, et al: Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104:1042-1050, 2004
5. Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 291:47-53, 2004
6. Kim N, Gross C, Curtis J, et al: The impact of clinical trials on the use of hormone replacement therapy: A population-based study. J Gen Intern Med 20:1026-1031, 2005
7. Ravdin PM, Cronin KA, Howlader N, et al: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674, 2007
8. Pearce CL, Chung K, Pike MC, et al: Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115:531-539, 2009
9. Mørch LS, Løkkegaard E, Andreasen AH, et al: Hormone therapy and ovarian cancer. JAMA 302:298-305, 2009
10. Hildebrand JS, Gapstur SM, Feigelson HS, et al: Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. Int J Cancer 127:2928-2935, 2010
11. Tsilidis KK, Allen NE, Key TJ, et al: Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22:1075-1084, 2011
12. Goodman MT, Shvetsov YB: Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev 18:132-139, 2009
13. Kim HJ, Fay MP, Feuer EJ, et al: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335-351, 2000
14. Holford TR: The estimation of age, period and cohort effects for vital rates. Biometrics 39:311-324, 1983
15. Rosenberg PS, Anderson WF: Age-period-cohort models in cancer surveillance research: Ready for prime time? Cancer Epidemiol Biomarkers Prev 20:1263-1268, 2011
16. Kohler BA, Ward E, McCarthy BJ, et al: Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714-736, 2011
17. Tucker TC, Howe HL: Measuring the quality of population-based cancer registries: The NAACCR perspective. J Reg Manage 28:41-44, 2001
18. Morabia A, Flandre P: Misclassification bias related to definition of menopausal status in case-control studies of breast cancer. Int J Epidemiol 21:222-228, 1992
19. National Cancer Institute: National Cancer Institute SEER*Stat software (ed version 7.0.9). http://seer.cancer.gov/seerstat/software/
20. Tarone RE, Chu KC: Evaluation of birth cohort patterns in population disease rates. Am J Epidemiol 143:85-91, 1996
21. Anderson WF, Camargo MC, Fraumeni JF Jr, et al: Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 303:1723-1728, 2010
22. Jemal A, Ma J, Rosenberg PS, et al: Increasing lung cancer death rates among young women in southern and midwestern states. J Clin Oncol 30: 2739-2744, 2012
23. North American Association of Central Cancer Registries: Who is certified. http://www.naaccr.org/Certification/WhoisCertified.aspx
24. Clegg LX, Feuer EJ, Midthune DN, et al: Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 94:1537-1545, 2002
25. Haas JS, Kaplan CP, Gerstenberger EP, et al: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140:184-188, 2004
26. Colditz GA: Decline in breast cancer incidence due to removal of promoter: Combination estrogen plus progestin. Breast Cancer Res 9:108, 2007
27. Gnagy S, Ming EE, Devesa SS, et al: Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology 11: 102-105, 2000
28. Asante A, Whiteman MK, Kulkarni A, et al: Elective oophorectomy in the United States: Trends and in-hospital complications, 1998-2006. Obstet Gynecol 116:1088-1095, 2010
29. Greene MH, Piedmonte M, Alberts D, et al: A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Design and baseline characteristics—A Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 17:594-604, 2008
30. Young RH: From Krukenberg to today: The ever present problems posed by metastatic tumors in the ovary—Part II. Adv Anat Pathol 14:149-177, 2007
31. Young RH: From Krukenberg to today: The ever present problems posed by metastatic tumors in the ovary—Part I. Historical perspective, general principles, mucinous tumors including the Krukenberg tumor. Adv Anat Pathol 13:205-227, 2006
32. Carlson J, Roh MH, Chang MC, et al: Recent advances in the understanding of the pathogenesis of serous carcinoma: The concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol (Oxf) 14:352-365, 2008
33. Cook LS, Weiss NS, Schwartz SM, et al: Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359-1364, 1995
34. Vogel VG, Costantino JP, Wickerham DL, et al: Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Ralox-ifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 3:696-706, 2010
35. Umar A, Dunn BK, Greenwald P: Future directions in cancer prevention. Nat Rev Cancer 12:835-848, 2012
36. Cronin KA, Ravdin PM, Edwards BK: Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat 117:223-224, 2009